A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Studien-Informationen

Ein-/Ausschlusskriterien

Studien-Rationale

Studien-Arme

• Experimental: Atezolizumab Monotherapy
  Participants will receive atezolizumab by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
• Experimental: Combined Agents with Atezolizumab
  Participants will receive treatment of atezolizumab with combined agent(s) as directed per the parent study. Participants will receive agent(s) in combination with atezolizumab at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
• Active Comparator: Comparator Treatment
  Participants will receive comparator treatment administration as directed per the parent study. Participants will receive comparator treatment at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.

Geprüfte Regime

• Atezolizumab (Tecentriq):
  Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
• Bevacizumab (Avastin):
  Bevacizumab will be administered as directed per the parent study.
• Alectinib (Alecensa):
  Alectinib will be administered as directed per the parent study.
• Cobimetinib (Cotellic):
  Cobimetinib will be administered as directed per the parent study.
• Vemurafenib (Zelboraf):
  Vemurafenib will be administered as directed per the parent study.
• FAP IL2V (simlukafusp alfa):
  FAP IL2V will be administered as directed per the parent study.
• Venetoclax (Venclexta):
  Venetoclax will be administered as directed per the parent study.
• Enzalutamide (Xtandi):
  Enzalutamide will be administered as directed per the parent study.
• Pembrolizumab (Keytruda):
  Pembrolizumab will be administered as directed per the parent study.
• Sunitinib (Sutent):
  Sunitinib will be administered as directed per the parent study.
• Niraparib (Zejula):
  Niraparib will be administered as directed per the parent study.
• Cabozantinib (Cometriq):
  Cabozantinib will be administered as directed per the parent study.
• Pemetrexed:
  Pemetrexed will be administered as directed per the parent study.
• Paclitaxel:
  Paclitaxel will be administered as directed per the parent study.
• Emactuzumab:
  Emactuzumab will be administered as directed per the parent study.
• Rucaparib:
  Rucaparib will be administered as directed per the parent study.

Quelle: ClinicalTrials.gov